The FDA approved BridgeBio’s acoramidis in a rare, genetic heart disease that’s expected to become an intense area of market competition, and a broad label …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The research review indicates that people with HIV, especially those with low CD4 cell counts, face greater risks of severe COVID-19 outcomes and have suboptimal
Many bedtime battles stem from children’s after dark worries, suggests a new national poll.
After a series of brutal setbacks that have chopped Bayer’s market value by around 21% in the last month, the German drugmaker unveiled an overhauled